InventisBio

InventisBio (益方生物科技（上海）股份有限公司) is an innovative drug R&D company based in Shanghai, China, focused on major disease areas including oncology, autoimmune diseases and metabolic diseases. According to its official website, all of its products are independently developed; it has advanced two innovative drugs to approval and has three candidate drugs in clinical trials, with two core products in registrational Phase III clinical trials. Its core pipeline includes the TYK2 inhibitor D-2570 and the oral selective estrogen receptor degrader (SERD) 泰瑞司群 (D-0502), both in registrational Phase III trials, and the URAT1 inhibitor 达比诺雷 (D-0120), which has completed Phase IIb trials. The company was co-founded by 王耀林（Yaolin Wang）and several other returnee PhDs.

InventisBio (益方生物科技（上海）股份有限公司) is an innovative drug R&D company based in China with a global vision, focusing on major disease areas such as oncology and metabolic diseases. It was co-founded by 王耀林（Yaolin Wang）and several other returnee PhDs, and its core R&D team has on average more than 20 years of experience leading new drug R&D and team management at multinational pharmaceutical companies. The company independently developed a series of patented innovative targeted drugs covering solid tumors such as non-small cell lung cancer, breast cancer and colorectal cancer, metabolic diseases such as hyperuricemia and gout, and autoimmune diseases such as psoriasis. As of the official website's account, the company has successfully advanced two innovative drugs to approval, has three candidate drugs in clinical trials, and two core products are in registrational Phase III clinical trials.

An innovative drug discovery company based in China with a global outlook, guided by the mission of addressing unmet clinical needs and dedicated to developing novel medicines with proprietary intellectual property that are created in China and intended for the world.

• D-2570

  TYK2 inhibitor; core product in registrational Phase III clinical trials.

• 泰瑞司群 (D-0502)

  Oral selective estrogen receptor degrader (SERD); core product in registrational Phase III clinical trials.

• 达比诺雷 (D-0120)

  URAT1 inhibitor; has completed Phase IIb clinical trials.

• YF087

  WRN inhibitor; preclinical candidate.

• YF550

  KIF18A inhibitor; preclinical candidate.

• YF057

  STAT6 oral degrader; preclinical candidate.

1. 1益方生物科技（上海）股份有限公司inventisbio.com
2. 2产品概览 – 益方生物科技（上海）股份有限公司inventisbio.com
3. 3公司介绍 – 益方生物科技（上海）股份有限公司inventisbio.com
4. 4InventisBio Co., Ltd. (China)wikidata.org